|
Name |
Aversin
|
| Molecular Formula | C20H16O7 | |
| IUPAC Name* |
(4S,8R)-18-hydroxy-2,16-dimethoxy-7,9-dioxapentacyclo[10.8.0.03,10.04,8.014,19]icosa-1,3(10),11,14(19),15,17-hexaene-13,20-dione
|
|
| SMILES |
COC1=CC2=C(C(=C1)O)C(=O)C3=C(C4=C(C=C3C2=O)O[C@@H]5[C@H]4CCO5)OC
|
|
| InChI |
InChI=1S/C20H16O7/c1-24-8-5-10-14(12(21)6-8)18(23)16-11(17(10)22)7-13-15(19(16)25-2)9-3-4-26-20(9)27-13/h5-7,9,20-21H,3-4H2,1-2H3/t9-,20+/m0/s1
|
|
| InChIKey |
RJMVOYLRGJZYAO-GWNMQOMSSA-N
|
|
| Synonyms |
Aversin; (-)-Aversin; 34080-91-6; OCJ5M677TN; Anthra(2,3-b)furo(3,2-d)furan-5,10-dione, 2,3,3a,12a-tetrahydro-6-hydroxy-4,8-dimethoxy-, (3aS-cis)-; UNII-OCJ5M677TN; (3aS-cis)-2,3,3a,12a-Tetrahydro-6-hydroxy-4,8-dimethoxyanthra(2,3-b)furo(3,2-d)furan-5,10-dione; 2,3,3a,12a-Tetrahydro-6-hydroxy-4,8-dimethoxyanthra(2,3-b)furo(3,2-d)furan-5,10-dione (3aS-cis)-; (4S,8R)-18-hydroxy-2,16-dimethoxy-7,9-dioxapentacyclo[10.8.0.03,10.04,8.014,19]icosa-1,3(10),11,14(19),15,17-hexaene-13,20-dione; ANTHRA(2,3-B)FURO(3,2-D)FURAN-5,10-DIONE, 2,3,3A,12A-TETRAHYDRO-6-HYDROXY-4,8-DIMETHOXY-, (3AS,12AR)-
|
|
| CAS | 34080-91-6 | |
| PubChem CID | 22296216 | |
| ChEMBL ID | NA |
Chemical Classification: |
|
|
|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
|---|---|---|---|---|---|---|---|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
| Molecular Weight: | 368.3 | ALogp: | 3.0 |
| HBD: | 1 | HBA: | 7 |
| Rotatable Bonds: | 2 | Lipinski's rule of five: | Accepted |
| Polar Surface Area: | 91.3 | Aromatic Rings: | 5 |
| Heavy Atoms: | 27 | QED Weighted: | 0.743 |
| Caco-2 Permeability: | -5.117 | MDCK Permeability: | 0.00001660 |
| Pgp-inhibitor: | 0.767 | Pgp-substrate: | 0.002 |
| Human Intestinal Absorption (HIA): | 0.05 | 20% Bioavailability (F20%): | 0.003 |
| 30% Bioavailability (F30%): | 0.004 |
| Blood-Brain-Barrier Penetration (BBB): | 0.001 | Plasma Protein Binding (PPB): | 88.50% |
| Volume Distribution (VD): | 0.548 | Fu: | 23.64% |
| CYP1A2-inhibitor: | 0.912 | CYP1A2-substrate: | 0.907 |
| CYP2C19-inhibitor: | 0.305 | CYP2C19-substrate: | 0.106 |
| CYP2C9-inhibitor: | 0.663 | CYP2C9-substrate: | 0.897 |
| CYP2D6-inhibitor: | 0.114 | CYP2D6-substrate: | 0.825 |
| CYP3A4-inhibitor: | 0.116 | CYP3A4-substrate: | 0.093 |
| Clearance (CL): | 8.086 | Half-life (T1/2): | 0.423 |
| hERG Blockers: | 0.004 | Human Hepatotoxicity (H-HT): | 0.253 |
| Drug-inuced Liver Injury (DILI): | 0.96 | AMES Toxicity: | 0.514 |
| Rat Oral Acute Toxicity: | 0.297 | Maximum Recommended Daily Dose: | 0.77 |
| Skin Sensitization: | 0.872 | Carcinogencity: | 0.306 |
| Eye Corrosion: | 0.003 | Eye Irritation: | 0.798 |
| Respiratory Toxicity: | 0.349 |
| Similar NPs | Similar Drugs | ||||||
|---|---|---|---|---|---|---|---|
| NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
| ENC000843 | ![]() |
0.659 | D0L1JW | ![]() |
0.289 | ||
| ENC003823 | ![]() |
0.587 | D04TDQ | ![]() |
0.288 | ||
| ENC005076 | ![]() |
0.557 | D06GCK | ![]() |
0.283 | ||
| ENC004539 | ![]() |
0.556 | D07MGA | ![]() |
0.280 | ||
| ENC002439 | ![]() |
0.529 | D0D4HN | ![]() |
0.278 | ||
| ENC002273 | ![]() |
0.524 | D0N1FS | ![]() |
0.274 | ||
| ENC000966 | ![]() |
0.517 | D0W8WB | ![]() |
0.274 | ||
| ENC005490 | ![]() |
0.516 | D01XWG | ![]() |
0.270 | ||
| ENC000362 | ![]() |
0.511 | D02LZB | ![]() |
0.269 | ||
| ENC003228 | ![]() |
0.505 | D09DHY | ![]() |
0.268 | ||